Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression
Objective clinical responses have been observed in approximately 50% of patients who
received non-myeloablative chemotherapy prior to the adoptive transfer of autologous
melanoma-reactive tumor-infiltrating lymphocytes (TILs). Recent studies carried out through
the use of antibodies directed against T-cell-receptor beta chain variable region (TRBV)
products, as well as by direct sequencing of the expressed TRBV gene products, indicated
that clinical responses in this trial were associated with the level of persistence of adoptively …
received non-myeloablative chemotherapy prior to the adoptive transfer of autologous
melanoma-reactive tumor-infiltrating lymphocytes (TILs). Recent studies carried out through
the use of antibodies directed against T-cell-receptor beta chain variable region (TRBV)
products, as well as by direct sequencing of the expressed TRBV gene products, indicated
that clinical responses in this trial were associated with the level of persistence of adoptively …